Dose-Effect Relationship of Kidney Function After SABR for Primary Renal Cell Carcinoma: TROG 15.03 FASTRACK II
- Author(s)
- Gaudreault, M; Hardcastle, N; Jackson, P; McIntosh, L; Higgs, B; Pryor, D; Sidhom, M; Dykyj, R; Moore, A; Kron, T; Siva, S;
- Details
- Publication Year 2024-11-01,Volume 120,Issue #3,Page 648-654
- Journal Title
- International Journal of Radiation Oncology, Biology, Physics
- Publication Type
- Research article
- Abstract
- PURPOSE: Stereotactic ablative body radiotherapy (SABR) is a novel option to treat primary renal cell carcinoma. However, a high radiation dose may be received by the treated kidney, which may affect its function posttreatment. This study investigates the dose-effect relationship of kidney SABR with posttreatment renal function. METHODS AND MATERIALS: This was a prespecified secondary endpoint of the multicenter FASTRACK II (Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney phase II) clinical trial (National Clinical Trial 02613819). Patients received either 26 Gy in a single fraction (SF) for tumors with a maximal diameter of 4 cm or less or 42 Gy in 3 fractions (multifraction [MF]) for larger tumors. To determine renal function change, (99m)Tc-dimercaptosuccinic acid (DMSA) single-photon emission computed tomography/computed tomography (SPECT/CT) scans were acquired, and the glomerular filtration rate was estimated at baseline, 12, and 24 months posttreatment. Imaging data sets were rigidly registered to the planning CT where kidneys were segmented to calculate dose-response curves. RESULTS: From 71 enrolled patients, 36 (51%) and 26 (37%) patients were included in this study based on availability of posttreatment data at 12 and 24 months, respectively. The ipsilateral kidney glomerular filtration rate decreased from baseline by 42% and 39% in the SF cohort and by 45% and 62% in the MF cohort, at 12 and 24 months, respectively (P < .03). The loss in renal function was 3.6%/Gy ± 0.8%/Gy and 4.5%/Gy ± 1.0%/Gy in the SF cohort and 1.7%/Gy ± 0.1%/Gy and 1.7%/Gy ± 0.2%/Gy in the MF cohort at 12 and 24 months, respectively. The major loss in renal function occurred in high-dose regions, where dose-response curves converged to a plateau. CONCLUSIONS: For the first time in a multicenter study, the dose-effect relationship at 12 and 24 months post-SABR treatment for primary renal cell carcinoma was quantified. Kidney function reduces linearly with dose up to 100 Gy BED(3).
- Publisher
- Elsevier
- Keywords
- Humans; *Carcinoma, Renal Cell/radiotherapy/diagnostic imaging/pathology/surgery; *Kidney Neoplasms/radiotherapy/diagnostic imaging; Male; *Radiosurgery/adverse effects/methods; Female; *Kidney/radiation effects/diagnostic imaging/physiopathology; Aged; Middle Aged; *Glomerular Filtration Rate; *Dose-Response Relationship, Radiation; Aged, 80 and over; Single Photon Emission Computed Tomography Computed Tomography; Radiopharmaceuticals; Adult; Technetium Tc 99m Dimercaptosuccinic Acid; Dose Fractionation, Radiation
- Department(s)
- Physical Sciences; Radiation Oncology
- Publisher's Version
- https://doi.org/10.1016/j.ijrobp.2024.04.066
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-10-03 03:37:15
Last Modified: 2024-10-03 03:37:33